- Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
-
Mak LY, Seto WK, Yuen MF
- KMID: 2538223
- Clin Mol Hepatol.
- 2023 Jan;29(1):191-193.
- doi: 10.3350/cmh.2022.0410
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”
-
Cheung KS, Mok CH, Seto WK, Yuen MF
- KMID: 2538218
- Clin Mol Hepatol.
- 2023 Jan;29(1):176-178.
- doi: 10.3350/cmh.2022.0377
-
- CITED
-
- Close
- SHARE
-
- Close
- Screening strategy for non-alcoholic fatty liver disease
-
Zhang S, Mak LY, Yuen MF, Seto WK
- KMID: 2539794
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S103-S122.
- doi: 10.3350/cmh.2022.0336
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately 25% of the general population worldwide, and is forecasted to increase global health burden in the... -
- CITED
-
- Close
- SHARE
-
- Close
- The role of different viral biomarkers on the management of chronic hepatitis B
-
Mak LY, Hui RWH, Fung J, Seto WK, Yuen MF
- KMID: 2541405
- Clin Mol Hepatol.
- 2023 Apr;29(2):263-276.
- doi: 10.3350/cmh.2022.0448
Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess... -
- CITED
-
- Close
- SHARE
-
- Close
- Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region
-
Zhu RX, Seto WK, Lai CL, Yuen MF
- KMID: 2411958
- Gut Liver.
- 2016 May;10(3):332-339.
- doi: 10.5009/gnl15257
Hepatocellular carcinoma (HCC) is the predominant primary liver cancer in many countries and is the third most common cause of cancer-related death in the Asia-Pacific region. The incidence of HCC... -
- CITED
-
- Close
- SHARE
-
- Close
- RNA interference as a novel treatment strategy for chronic hepatitis B infection
-
Hui RWH, Mak LY, Seto WK, Yuen MF
- KMID: 2531368
- Clin Mol Hepatol.
- 2022 Jul;28(3):408-424.
- doi: 10.3350/cmh.2022.0012
Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved... -
- CITED
-
- Close
- SHARE
-
- Close
- New Biomarkers of Chronic Hepatitis B
-
Mak LY, Seto WK, Fung J, Yuen MF
- KMID: 2464306
- Gut Liver.
- 2019 Nov;13(6):589-595.
- doi: 10.5009/gnl18425
Chronic hepatitis B (CHB) infection leads to clinically heterogeneous disease outcomes. Different viral markers are utilized to monitor treatment effects and predict risk of complications in patients with CHB. Hepatitis... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective
-
Hui RWH, Mak LY, Cheung TT, Lee VHF, Seto WK, Yuen MF
- KMID: 2541401
- Clin Mol Hepatol.
- 2023 Apr;29(2):217-229.
- doi: 10.3350/cmh.2022.0399
Hepatocellular carcinoma (HCC) is a major public health burden in Hong Kong, and chronic hepatitis B is the most common HCC etiology in our region. With the high case load,... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B
-
Hui KY, Fung J, Cheung KS, Mak LY, Seto WK, Yuen MF
- KMID: 2540416
- Gut Liver.
- 2023 Mar;17(2):280-287.
- doi: 10.5009/gnl220122
Background/Aims: Hepatitis B surface antigen (HBsAg) seroclearance remains uncommon in chronic hepatitis B (CHB) infection. During acute flares of CHB (AFOCHB), alanine aminotransferase elevation reflects a mounting immune response toward... -
- CITED
-
- Close
- SHARE
-
- Close
- Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
-
Mak LY, Ko KL, To WP, Wong DKH, Seto WK, Fung J, Yuen MF
- KMID: 2506442
- Gut Liver.
- 2020 Sep;14(5):665-668.
- doi: 10.5009/gnl19434
Serum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. We investigated the longitudinal profile of... -
- CITED
-
- Close
- SHARE
-
- Close
- COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis
-
Cheung KS, Mok CH, Mao X, Zhang R, Hung IF, Seto WK, Yuen MF
- KMID: 2534353
- Clin Mol Hepatol.
- 2022 Oct;28(4):890-911.
- doi: 10.3350/cmh.2022.0087
Background/Aims: Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology,... -
- CITED
-
- Close
- SHARE
-
- Close
- Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes
-
Lee CH, Seto WK, Ieong K, Lui DT, Fong CH, Wan HY, Chow WS, Woo YC, Yuen MF, Lam KS
- KMID: 2513297
- Endocrinol Metab.
- 2021 Feb;36(1):134-145.
- doi: 10.3803/EnM.2020.887
Background: In non-alcoholic fatty liver disease (NAFLD), transient elastography (TE) is an accurate non-invasive method to identify patients at risk of advanced fibrosis (AF). We developed a diabetes-specific, non-invasive liver... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients
-
Cheung KS, Lam LK, Hui RWH, Mao X, Zhang RR, Chan KH, Hung IF, Seto WK, Yuen MF
- KMID: 2531378
- Clin Mol Hepatol.
- 2022 Jul;28(3):553-564.
- doi: 10.3350/cmh.2022.0082
Background/Aims: Studies of hepatic steatosis (HS) effect on COVID-19 vaccine immunogenicity are lacking. We aimed to compare immunogenicity of BNT162b2 and CoronaVac among moderate/severe HS and control subjects. Methods: Two hundred... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
-
Mak LY, Wong D, Kuchta A, Hilfiker M, Hamilton A, Chow N, Mao X, Seto WK, Yuen MF
- KMID: 2538211
- Clin Mol Hepatol.
- 2023 Jan;29(1):146-162.
- doi: 10.3350/cmh.2022.0172
Background/Aims: We investigated the dynamics of serum HBV pre-genomic RNA (pgRNA) and hepatitis B core-related antigen (HBcrAg) in patients receiving nucleos(t)ide analogues (NAs) and their predictability for favourable suppression of... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
-
Yap DYH, Liu KSH, Hsu YC, Wong GLH, Tsai MC, Chen CH, Hsu CS, Hui YT, Li MKK, Liu CH, Kan YM, Yu ML, Yuen MF
- KMID: 2507974
- Clin Mol Hepatol.
- 2020 Oct;26(4):554-561.
- doi: 10.3350/cmh.2020.0058
Background/Aims: Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
-
Yuen MF, Chuang WL, Peng CY, Jeng WJ, Su WW, Chang TT, Chen CY, Hsu YC, De La Rosa G, Ahmad A, Luo E, Conery AL
- KMID: 2557390
- Clin Mol Hepatol.
- 2024 Jul;30(3):375-387.
- doi: 10.3350/cmh.2023.0535
Background/Aims: Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells.... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
-
Hou J, Gane E, Balabanska R, Zhang W, Zhang J, Lim TH, Xie Q, Yeh CT, Yang SS, Liang X, Komolmit P, Leerapun A, Xue Z, Chen E, Zhang Y, Xie Q, Chang TT, Hu TH, Lim SG, Chuang WL, Leggett B, Bo Q, Zhou X, Triyatni M, Zhang W, Yuen MF
- KMID: 2554426
- Clin Mol Hepatol.
- 2024 Apr;30(2):191-205.
- doi: 10.3350/cmh.2023.0422
Background/Aims: Four-week treatment of linvencorvir (RO7049389) was generally safe and well tolerated, and showed anti-viral activity in chronic hepatitis B (CHB) patients. This study evaluated the efficacy, safety, and pharmacokinetics... -
- CITED
-
- Close
- SHARE
-
- Close
